Effect of treatment with the cholinesterase inhibitor rivastigmine on vesicular acetylcholine transporter and choline acetyltransferase in rat brain

Clinical and Experimental Hypertension

Volumn 26, Issue 4, 2004, Pages 363-373

  Tayebati, Seyed Khosrow ^a   Di Tullio, Maria Antonietta ^a   Amenta, Francesco ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Choline acetyltransferase; Hypertension; Rat; Rivastigmine; Vesicular acetylcholine transporter

Indexed keywords

CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE INHIBITOR; RIVASTIGMINE; VESICULAR ACETYLCHOLINE TRANSPORTER;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CEREBELLUM; CHOLINERGIC TRANSMISSION; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FRONTAL CORTEX; HIPPOCAMPUS; HYPERTENSION; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MULTIINFARCT DEMENTIA; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; BLOOD PRESSURE; BRAIN; BRAIN CHEMISTRY; CARBAMATES; CHOLINE O-ACETYLTRANSFERASE; CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; HYPERTENSION; MALE; MEMBRANE TRANSPORT PROTEINS; PHENYLCARBAMATES; RATS; RATS, INBRED SHR; RATS, WISTAR; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS; VESICULAR TRANSPORT PROTEINS;

EID: 2542427736     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.1081/CEH-120034140     Document Type: Conference Paper

References (31)

1. Drachman DA, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch Neurol 1974; 39:113-121.
2. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2:1403-1404.
3. Bowen DM. Biochemistry of dementias. Proc R Soc Med 1977; 70:351-353.
4. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408-417.
5. Gottfries CG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia 1994; 5:163-167.
6. Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 1996; 103:1211-1220.
7. Wallin A, Alafuzoff I, Carlsson A, Eckernas SA, Gottfries CG, Karlsson I, Svennerholm L, Winblad B. Neurotransmitter deficits in a non-multi-infarct category of vascular dementia. Acta Neurol Scand 1989; 79:397-406.
8. Birkenhäger WH, Forette F, Seux ML, Wang JG, Staessen JA. Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med 2001; 161:152-156.
9. Forette F, Boller F. Hypertension and the risk of dementia in the elderly. Am J Med 1991; 90:14S-19S.
10. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000; 4:CD001191.
11. Lestage P. Pharmacologic treatment for cognitive disorders: an upd. Therapie 2000; 55:507-512.
12. Maelicke A. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl). Int J Clin Pract, Suppl 2001; 120:24-28.
13. Erkinjunti T. Cognitive decline and treatment options for patients with vascular dementia. Acta Neurol Scand 2002; 106:15-18.
14. Blusztajn JK, Wurtman RJ. Choline and cholinergic neurons. Science 1983; 221:614-620.
15. Tucek S. The synthesis of acetylcholine: twenty years of progress. Prog Brain Res 1990; 84:467-477.
16. Ellman GL, Courtney KD, Andres V Jr, Featherstone RM. A new and rapid colorimetric determination of acetilcholinesterase activity. Biochem Pharmacol 1961; 7:88-95.
17. Lowry OH, Rosebrought NJ, Fau AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951; 193:265-275.
18. Tayebati SK, El-Assouad D, Ricci A, Amenta F. Immunochemical and immunocytochemical characterization of cholinergic markers in human peripheral blood lymphocytes. J Neuroimmunol 2002; 132:147-155.
19. Bartus RT, Dean RL, Flicker C. Cholinergic psychopharmacology: an integration of human and animal research on memory. In Psychopharmacology: the Third Generation of Progress. Meltzer HY, ed.; Raven Press: New York, 1987, 219-232.
20. Dunnet S, Everitt JB, Robbins TW. The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. Trends Neurosci 1991; 14:494-501.
21. Biegon A, Duvdevani R, Greenberger V, Segal M. Aging and brain cholinergic muscarinic receptors: an autoradiographic study in the rat. J Neurochem 1988; 57:1381-1385.
22. Michalek H, Fortuna S, Pintor A. Age-related differences in brain choline acetyltransferase, cholinesterase and muscarinic receptor sites in two strains of rats. Neurobiol Aging 1989; 10:143-148.
23. Gualtieri F, Dei S, Manetti D, Romanelli MN, Scapecchi S, Teodori E. The medicinal chemistry of Alzheimer's and Alzheimer's-like diseases with emphasis on the cholinergic hypothesis. Farmaco 1995; 50:489-503.
24. Oda Y. Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. Pathol Int 1999; 49:921-937.
25. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993; 98:431-438.
26. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998; 20:634-647.
27. Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett 1999; 260:5-8.
28. Ohara T, Tanaka K, Fukaya H, Depura N, Iimura A, Seno N. SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats. Behav Brain Res 1997; 83:229-233.
29. Bravo D, Parsons SM. Microscopic kinetics and structure-function analysis in the vesicular acetylcholine transporter. Neurochem Int 2002; 41:285-289.
30. Sabbatini M, Tomassoni D, Amenta F. Hypertensive brain damage: comparative evaluation of protective effect of treatment with dihydropyridine derivatives in spontaneously hypertensive rats. Mech Ageing Dev 2001; 122:2085-2105.
31. Hernandez CM, Hoifodt H, Terry AV Jr. Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression. J Psychiatry Neurosci 2003; 28:197-209.